文献速递乳腺癌

RSClinN+工具的开发与验证:用于预测激素受体阳性、淋巴结阳性乳腺癌的预后和化疗获益

Development and Validation of the RSClinN+ Tool to Predict Prognosis and Chemotherapy Benefit for Hormone Receptor-Positive, Node-Positive Breast Cancer.
PubMed 文献 · J Clin Oncol · 2024-12-02

研究利用S1007和S8814试验中5283例激素受体阳性、人表皮生长因子受体2阴性、淋巴结阳性乳腺癌患者数据,开发整合21基因复发评分与临床病理因素的RSClinN+工具,用于按绝经状态个体化预测复发风险和化疗绝对获益。RSClinN+预后信息优于单独复发评分或临床病理模型,外部验证中风险估计有预后价值且与观察风险一致。

要点

  • RSClinN+整合复发评分与分级、肿瘤大小、年龄,按绝经状态预测5年无浸润性疾病生存。
  • 绝经后女性中复发评分与化疗内分泌治疗获益存在交互作用(P = .016)。
  • 外部验证中RSClinN+风险估计有预后价值(风险比1.75,95%CI 1.38至2.20)。

核心结论

  • RSClinN+较单独复发评分或单独临床数据能提供更好的个体化预后和化疗绝对获益估计,可用于患者咨询。

研究设计与样本

  • 使用S1007试验(N = 4,916)和S8814试验(N = 367)共5,283例接受化疗内分泌治疗或单独内分泌治疗的患者数据开发工具。
  • 采用按试验分层的Cox比例风险回归模型分别估计绝经前和绝经后女性的5年无浸润性疾病生存。
  • 在Clalit健康服务登记处592例淋巴结阳性患者中进行外部验证。

主要发现

  • RSClinN+预后信息优于单独复发评分模型(绝经前P = .034;绝经后P < .001)。
  • RSClinN+预后信息优于单独临床病理模型(绝经前P = .002;绝经后P < .001)。
  • 绝经后女性中复发评分与化疗内分泌治疗获益存在交互作用(P = .016),复发评分0-50范围内RSClinN+估计的化疗内分泌治疗绝对获益从<0.1%到21.5%。
  • 绝经前复发评分≤25的患者中复发评分与化疗内分泌治疗获益无显著交互作用。
  • 外部验证中RSClinN+风险估计有预后价值(风险比1.75,95%CI 1.38至2.20),与观察风险一致(Lin一致性0.92)。

临床怎么用

  • 作者认为RSClinN+可用于患者咨询。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Clinicopathological factors and the 21-gene Oncotype DX Breast Recurrence Score (RS) test both influence prognosis. Our goal was to develop a new tool, RSClinN+, to individualize recurrence risk and chemotherapy benefit predictions by menopausal status for patients with HR+/human epidermal growth factor receptor 2-negative, lymph node-positive breast cancer by integrating the RS result with clinicopathological factors (grade, tumor size, age). METHODS: We used patient-level data from 5,283 patients treated with chemoendocrine therapy (CET) versus endocrine therapy alone (ET) in the S1007 (N = 4,916) and S8814 (N = 367) trials to develop the tool. Cox proportional hazards regression models stratified by trial were used to estimate 5-year invasive disease-free survival for pre- and postmenopausal woman, respectively. The integrated RSClinN+ model was compared with RS alone and clinicopathological models using likelihood ratio tests. Absolute CET benefit was estimated as the difference between ET and CET risk estimates. Validation of RSClinN+ was performed in 592 patients with node-positive disease in the Clalit Health Services registry. RESULTS: RSClinN+ provides better prognostic information than RS model alone (premenopausal P = .034; postmenopausal P < .001) or clinicopathological model alone (premenopausal P = .002; postmenopausal, P < .001). In postmenopausal women, RS showed interaction with CET benefit (P = .016), with RSClinN+ absolute CET benefit ranging from <0.1% to 21.5% over RS ranges 0-50. In premenopausal patients with RS ≤25, there was no significant interaction between RS and CET benefit. In external validation, RSClinN+ risk estimates were prognostic (hazard ratio, 1.75 [95% CI, 1.38 to 2.20]) and concordant with observed risk (Lin's concordance, 0.92). CONCLUSION: RSClinN+ provides improved estimates of prognosis and absolute CET benefit for individual patients compared with RS or with clinical data alone and could be used in patient counseling.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Pusztai L, Hoag JR, Albain KS, et al. Development and Validation of the RSClinN+ Tool to Predict Prognosis and Chemotherapy Benefit for Hormone Receptor-Positive, Node-Positive Breast Cancer. J Clin Oncol. 2024. PMID: 39621968. doi:10.1200/JCO-24-01507

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。